494 related articles for article (PubMed ID: 18701762)
1. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
3. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation.
Larangé A; Antonios D; Pallardy M; Kerdine-Römer S
J Leukoc Biol; 2009 Apr; 85(4):673-83. PubMed ID: 19164127
[TBL] [Abstract][Full Text] [Related]
4. Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8.
Janke M; Poth J; Wimmenauer V; Giese T; Coch C; Barchet W; Schlee M; Hartmann G
J Allergy Clin Immunol; 2009 May; 123(5):1026-33. PubMed ID: 19361845
[TBL] [Abstract][Full Text] [Related]
5. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells.
Smits EL; Cools N; Lion E; Van Camp K; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Cancer Immunol Immunother; 2010 Jan; 59(1):35-46. PubMed ID: 19449004
[TBL] [Abstract][Full Text] [Related]
6. Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8.
Lan T; Putta MR; Wang D; Dai M; Yu D; Kandimalla ER; Agrawal S
Biochem Biophys Res Commun; 2009 Aug; 386(3):443-8. PubMed ID: 19523922
[TBL] [Abstract][Full Text] [Related]
7. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.
Lan T; Kandimalla ER; Yu D; Bhagat L; Li Y; Wang D; Zhu F; Tang JX; Putta MR; Cong Y; Trombino AF; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13750-5. PubMed ID: 17698957
[TBL] [Abstract][Full Text] [Related]
8. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells.
Hurst J; Prinz N; Lorenz M; Bauer S; Chapman J; Lackner KJ; von Landenberg P
Immunobiology; 2009; 214(8):683-91. PubMed ID: 19249118
[TBL] [Abstract][Full Text] [Related]
9. Synthetic agonists of Toll-like receptors 7, 8 and 9.
Agrawal S; Kandimalla ER
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1461-7. PubMed ID: 18031246
[TBL] [Abstract][Full Text] [Related]
10. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
Hammerbeck DM; Burleson GR; Schuller CJ; Vasilakos JP; Tomai M; Egging E; Cochran FR; Woulfe S; Miller RL
Antiviral Res; 2007 Jan; 73(1):1-11. PubMed ID: 16959331
[TBL] [Abstract][Full Text] [Related]
11. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
12. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7.
Lai CY; Liu YL; Yu GY; Maa MC; Leu TH; Xu C; Luo Y; Xiang R; Chuang TH
Vaccine; 2014 Sep; 32(43):5593-9. PubMed ID: 25131730
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
[TBL] [Abstract][Full Text] [Related]
14. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
15. CD14+ cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands.
Buza J; Benjamin P; Zhu J; Wilson HL; Lipford G; Krieg AM; Babiuk LA; Mutwiri GK
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):273-82. PubMed ID: 18789542
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.
Krieg AM; Vollmer J
Immunol Rev; 2007 Dec; 220():251-69. PubMed ID: 17979852
[TBL] [Abstract][Full Text] [Related]
17. TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation.
Assier E; Marin-Esteban V; Haziot A; Maggi E; Charron D; Mooney N
J Leukoc Biol; 2007 Jan; 81(1):221-8. PubMed ID: 17023556
[TBL] [Abstract][Full Text] [Related]
18. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides.
Jurk M; Kritzler A; Schulte B; Tluk S; Schetter C; Krieg AM; Vollmer J
Eur J Immunol; 2006 Jul; 36(7):1815-26. PubMed ID: 16783850
[TBL] [Abstract][Full Text] [Related]
19. Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8.
Lan T; Bhagat L; Wang D; Dai M; Kandimalla ER; Agrawal S
Bioorg Med Chem Lett; 2009 Apr; 19(7):2044-7. PubMed ID: 19269175
[TBL] [Abstract][Full Text] [Related]
20. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
Dumitru CD; Antonysamy MA; Gorski KS; Johnson DD; Reddy LG; Lutterman JL; Piri MM; Proksch J; McGurran SM; Egging EA; Cochran FR; Lipson KE; Tomai MA; Gullikson GW
Cancer Immunol Immunother; 2009 Apr; 58(4):575-87. PubMed ID: 18791716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
